- Home
- ELAB vs SPRB Comparison
ELAB vs SPRB Comparison
Compare ELAB & SPRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- SPRB
- Stock Information
- Founded
- ELAB 2020
- SPRB 2014
- Country
- ELAB United States
- SPRB United States
- Employees
- ELAB N/A
- SPRB N/A
- Industry
- ELAB
- SPRB Medicinal Chemicals and Botanical Products
- Sector
- ELAB
- SPRB Health Care
- Exchange
- ELAB Nasdaq
- SPRB Nasdaq
- Market Cap
- ELAB 6.6M
- SPRB 5.5M
- IPO Year
- ELAB 2023
- SPRB 2020
- Fundamental
- Price
- ELAB $2.22
- SPRB $0.13
- Analyst Decision
- ELAB
- SPRB Hold
- Analyst Count
- ELAB 0
- SPRB 5
- Target Price
- ELAB N/A
- SPRB $1.75
- AVG Volume (30 Days)
- ELAB 1.1M
- SPRB 2.6M
- Earning Date
- ELAB 05-14-2025
- SPRB 04-15-2025
- Dividend Yield
- ELAB N/A
- SPRB N/A
- EPS Growth
- ELAB N/A
- SPRB N/A
- EPS
- ELAB N/A
- SPRB N/A
- Revenue
- ELAB N/A
- SPRB $4,911,000.00
- Revenue This Year
- ELAB N/A
- SPRB N/A
- Revenue Next Year
- ELAB N/A
- SPRB $312.50
- P/E Ratio
- ELAB N/A
- SPRB N/A
- Revenue Growth
- ELAB N/A
- SPRB N/A
- 52 Week Low
- ELAB $2.15
- SPRB $0.12
- 52 Week High
- ELAB $1,064.00
- SPRB $0.87
- Technical
- Relative Strength Index (RSI)
- ELAB 27.63
- SPRB 23.23
- Support Level
- ELAB $2.26
- SPRB $0.11
- Resistance Level
- ELAB $2.96
- SPRB $0.14
- Average True Range (ATR)
- ELAB 0.55
- SPRB 0.03
- MACD
- ELAB 0.07
- SPRB -0.01
- Stochastic Oscillator
- ELAB 2.06
- SPRB 11.12
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About SPRB Spruce Biosciences Inc.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company is initially developing its wholly-owned product candidate, tildacerfont, as the potential first non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia (CAH).